Gilead Sciences (GILD) Trading Down 0% Following Analyst Downgrade

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0% during trading on Thursday after TheStreet downgraded the stock from a b- rating to a c rating. The company traded as low as $78.07 and last traded at $78.22. 13,742,484 shares were traded during mid-day trading, an increase of 37% from the average session volume of 10,055,273 shares. The stock had previously closed at $78.22.

A number of other equities analysts also recently issued reports on GILD. Mizuho set a $83.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Monday. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Bank of America lifted their price target on Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a research note on Wednesday. Morgan Stanley cut their price target on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Leerink Swann cut their price target on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $86.56.

In other news, EVP James R. Meyers sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the transaction, the executive vice president now owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold a total of 578,333 shares of company stock worth $44,100,508 in the last 90 days. Company insiders own 1.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Welch Investments LLC purchased a new position in Gilead Sciences in the third quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new position in Gilead Sciences in the third quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new position in Gilead Sciences in the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Gilead Sciences in the second quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the last quarter. Institutional investors and hedge funds own 75.84% of the company’s stock.

The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The firm has a market cap of $102,150.00, a P/E ratio of 22.48, a P/E/G ratio of -1.77 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 48.88% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the prior year, the business earned $2.70 earnings per share. Gilead Sciences’s revenue for the quarter was down 18.7% on a year-over-year basis. research analysts expect that Gilead Sciences, Inc. will post 6.47 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a $0.57 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 annualized dividend and a yield of 2.91%. Gilead Sciences’s dividend payout ratio is presently 59.77%.

ILLEGAL ACTIVITY WARNING: This piece was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/gilead-sciences-gild-trading-down-0-following-analyst-downgrade.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply